VR headsets could boost power of Fast-Acting depression drug
NCT ID NCT06781697
Summary
This small pilot study aims to see if combining a fast-acting depression medication (ketamine) with immersive virtual reality (VR) is a better treatment than ketamine alone for adults with depression that hasn't responded to other medications. All 31 participants will receive standard ketamine infusions, but half will also use a VR headset during treatment. The main goal is to test if running a larger future trial is feasible, while also checking if the combination improves depression symptoms more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.